Arbutus Biopharma Corp Operating Lease Right-of-Use Assets
Arbutus Biopharma Corp (ABUS) had Operating Lease Right-of-Use Assets of $0 as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-03-23
- 2025-12-31: Operating Lease, Right-of-Use Asset $0.00.
- 2025-09-30: Operating Lease, Right-of-Use Asset $0.00.
- 2025-06-30: Operating Lease, Right-of-Use Asset $0.00.
- 2025-03-31: Operating Lease, Right-of-Use Asset $0.00.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.05M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.14M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.24M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.33M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.42M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.50M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.58M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.67M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.74M 10-K · filed 2024-03-05 |
| 2022-09-30 | $1.82M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.92M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $2.01M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $2.09M 10-K · filed 2023-03-02 |
| 2021-09-30 | $2.17M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $2.23M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.31M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $2.40M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.49M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.58M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $2.66M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.74M 10-K · filed 2021-03-04 |
| 2019-09-30 | $2.82M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $2.90M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $3.08M 10-Q · filed 2019-05-06 |
| 2019-01-01 | $3.20M 10-Q · filed 2019-11-06 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |